Insider · CIK 0001862109
venBio Global Strategic Fund IV, L.P.
Files at ATTO (Attovia Therapeutics, Inc.). First filing Aug 10, 2026, latest Aug 10, 2026.
In brief
venBio Global Strategic Fund IV, L.P. files SEC Form 4 as 10% owner at ATTO (Attovia Therapeutics, Inc.). Since Aug 10, 2026, venBio Global Strategic Fund IV, L.P. has reported 1 open-market buy worth $6.5M and 0 open-market sells worth $0, the latest filed on Aug 10, 2026.
A track record needs three past buys with six months of prices behind them; venBio Global Strategic Fund IV, L.P. has 0, so none is measured yet.
The newest scored trade: bought $6.5M of ATTO on Aug 6, 2026, filed Aug 10, 2026, scored 50 (moderate). In the last 12 months: 1 buy worth $6.5M and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ATTO: Attovia Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 50Moderate | Attovia Therapeutics, Inc. | $6.5M 382,352 shares | +10% | - |
Transactions
Every row this insider has filed, 7 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 6, 2026 | ATTO Attovia Therapeutics, Inc. | CConversion Common Stock | +2,311,870 | - | - | 2,311,870 | Aug 10, 2026 |
| Aug 6, 2026 | ATTO Attovia Therapeutics, Inc. | CConversion Common Stock | +821,998 | - | - | 3,133,868 | Aug 10, 2026 |
| Aug 6, 2026 | ATTO Attovia Therapeutics, Inc. | CConversion Common Stock | +665,147 | - | - | 3,799,015 | Aug 10, 2026 |
| Aug 6, 2026 | ATTO Attovia Therapeutics, Inc. | POpen-market purchase Common Stock | +382,352 | $17.00 | $6.5M | 4,181,367 | Aug 10, 2026 |
| Aug 6, 2026 | ATTO Attovia Therapeutics, Inc. | CConversion Series A Preferred Stockderivative | -21,477,273 | $0.00 | $0 | 0 | Aug 10, 2026 |
| Aug 6, 2026 | ATTO Attovia Therapeutics, Inc. | CConversion Series B Preferred Stockderivative | -7,636,362 | $0.00 | $0 | 0 | Aug 10, 2026 |
| Aug 6, 2026 | ATTO Attovia Therapeutics, Inc. | CConversion Series C Preferred Stockderivative | -6,179,219 | $0.00 | $0 | 0 | Aug 10, 2026 |
Questions about venBio Global Strategic Fund IV, L.P.
Answered from the filings on this page, as of the latest one.
Is venBio Global Strategic Fund IV, L.P. buying or selling?
In the last 12 months venBio Global Strategic Fund IV, L.P. reported 1 open-market buy worth $6.5M and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $6.5M of ATTO on Aug 6, 2026. Grants, option exercises and tax withholding are not counted.
How did venBio Global Strategic Fund IV, L.P.'s past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and venBio Global Strategic Fund IV, L.P. has 0.
Where does venBio Global Strategic Fund IV, L.P. file Form 4?
venBio Global Strategic Fund IV, L.P. has filed Form 4 at ATTO (Attovia Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.